Screener / SEC EDGAR /CIK 0001420800 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Enovis CORP ENOV

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 2 of 2 range targets
Below the range 0 below the last range given

The numbers ENOV said it expected, in its earnings releases, next to what it then reported for the same period. 1 full-year target was dropped quietly: the next release, before the year ended, gave other targets for that year but said nothing about this one.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given $425.00M to $435.00M release Feb 26, 2026
Kept $425.00M to $435.00M release May 7, 2026
Kept $425.00M to $435.00M release Aug 6, 2026
Raised $428.00M to $438.00M release Nov 5, 2026
– No standard number
The company's words
2026 Financial Outlook … Adjusted EBITDA is expected to be in a range of $425-435 million. release Feb 26, 2026
2026 Financial Outlook … Adjusted EBITDA is expected to be in a range of $425-435 million. release May 7, 2026
2026 Financial Outlook … Adjusted EBITDA is expected to be in a range of $425-435 million. release Aug 6, 2026
2026 Financial Outlook … Adjusted EBITDA guidance is raised to a range of $428-438 million, as compared to the prior outlook of $425-435 million. release Nov 5, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $3.52 to $3.73 release Feb 26, 2026
Kept $3.52 to $3.73 release May 7, 2026
Kept $3.52 to $3.73 release Aug 6, 2026
Raised $3.58 to $3.79 release Nov 5, 2026
– No standard number
The company's words
Full-year adjusted earnings per share is expected to be in the range of $3.52 to $3.73 release Feb 26, 2026
Full-year adjusted earnings per share is expected to be in the range of $3.52 to $3.73. release May 7, 2026
Full-year adjusted earnings per share is expected to be in a range of $3.52 to $3.73. release Aug 6, 2026
Full-year adjusted earnings per share guidance is raised from $3.52-3.73 to $3.58-3.79. release Nov 5, 2026
Revenue
Fiscal 2026
Given $2.31B to $2.37B release Feb 26, 2026
Kept $2.31B to $2.37B release May 7, 2026
Kept $2.31B to $2.37B release Aug 6, 2026
Lowered $2.32B to $2.35B release Nov 5, 2026
– Not reported yet
The company's words
2026 Financial Outlook … Revenue is expected to approximate $2.31-2.37 billion, which incorporates 4-6% organic revenue growth. release Feb 26, 2026
2026 Financial Outlook … Revenue is expected to approximate $2.31-2.37 billion, which incorporates 4-6% organic revenue growth. release May 7, 2026
2026 Financial Outlook … Revenue is expected to be in a range of $2.31-2.37 billion, which incorporates 4-6% organic revenue growth. release Aug 6, 2026
2026 Financial Outlook … Revenue guidance is narrowed to a range of $2.32-2.35 billion, versus prior expectations of $2.31-2.37 billion. release Nov 5, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $405.00M to $415.00M release Feb 26, 2025
Lowered $385.00M to $395.00M release May 8, 2025
Raised $392.00M to $402.00M release Aug 7, 2025
Raised $395.00M to $405.00M release Nov 6, 2025
– No standard number
The company's words
2025 Financial Outlook … Adjusted EBITDA is forecasted to be $405-415 million, which represents 60-70 bps expansion Y/Y. Full-year adjusted earnings per share are expected to be in the range of $3.10-$3.25. release Feb 26, 2025
2025 Financial Outlook … Adjusted EBITDA is forecasted to be $385-395 million, as compared to the prior outlook of $405-415 million, and now includes $20mm of tariff related impact. release May 8, 2025
2025 Financial Outlook … Adjusted EBITDA is forecasted to be $392-402 million, as compared to the prior outlook of $385-395 million. release Aug 7, 2025
2025 Financial Outlook … Adjusted EBITDA is forecasted to be $395-405 million, as compared to the prior outlook of $392-402 million. release Nov 6, 2025
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $3.10 to $3.25 release Feb 26, 2025
Dropped quietly release May 8, 2025 ⓘ
– No standard number
The company's words
2025 Financial Outlook … Adjusted EBITDA is forecasted to be $405-415 million, which represents 60-70 bps expansion Y/Y. Full-year adjusted earnings per share are expected to be in the range of $3.10-$3.25. release Feb 26, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $2.19B to $2.22B release Feb 26, 2025
Raised $2.22B to $2.25B release May 8, 2025
Raised $2.25B to $2.27B release Aug 7, 2025
Lowered $2.24B to $2.27B release Nov 6, 2025
$2.25B
10-K filed 2026-02-26
Within the range
The company's words
2025 Financial Outlook … Revenue is expected to approximate $2.19-2.22 billion, which incorporates 6-6.5% organic revenue growth. release Feb 26, 2025
2025 Financial Outlook … Revenue is expected to be in the range of $2.22-2.25 billion, versus prior expectations of $2.19-2.22 billion. release May 8, 2025
2025 Financial Outlook … Revenue is expected to be in the range of $2.245-2.275 billion, versus prior expectations of $2.220-2.250 billion. release Aug 7, 2025
2025 Financial Outlook … Revenue is expected to be in the range of $2.24-2.27 billion, versus prior expectations of $2.245-2.275 billion. release Nov 6, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $365.00M to $380.00M release Feb 22, 2024
Raised $368.00M to $383.00M release May 2, 2024
Kept $368.00M to $383.00M release Aug 7, 2024
Narrowed $373.00M to $378.00M release Nov 6, 2024
– No standard number
The company's words
2024 Financial Outlook … Adjusted EBITDA is forecasted to be $365-$380 million which is inclusive of $70-75 million from Lima. release Feb 22, 2024
2024 Financial Outlook … Full-year revenue is expected to approximate $2.06-2.16 billion versus prior expectations of $2.05-2.15 billion, and adjusted EBITDA is forecasted to be $368-383 million as compared with the previous outlook of $365-380 million. release May 2, 2024
2024 Financial Outlook … Full-year revenue is estimated at $2.08-$2.13 billion, and adjusted EBITDA is forecasted to be $368-$383 million. release Aug 7, 2024
Full-year revenue is estimated at $2.10 billion, and adjusted EBITDA is forecasted to be $373-$378 million. release Nov 6, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.50 to $2.65 release Feb 22, 2024
Raised $2.62 to $2.77 release Aug 7, 2024
Raised $2.75 to $2.80 release Nov 6, 2024
– No standard number
The company's words
Full-year adjusted earnings per diluted share are expected to be in the range of $2.50-$2.65. release Feb 22, 2024
2024 Financial Outlook … The Company also raised its full- year adjusted earnings per diluted share guidance from $2.52-$2.67 to $2.62-$2.77. release Aug 7, 2024
The Company also raised its full-year adjusted earnings per diluted share guidance from $2.62-$2.77 to $2.75-$2.80. release Nov 6, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $2.05B to $2.15B release Feb 22, 2024
Raised $2.06B to $2.16B release May 2, 2024
Lowered $2.08B to $2.13B release Aug 7, 2024
$2.11B
10-K filed 2025-02-26
Within the range
The company's words
2024 Financial Outlook … Revenue is expected to approximate $2.05-2.15 billion. release Feb 22, 2024
Full-year revenue is expected to approximate $2.06-2.16 billion versus prior expectations of $2.05-2.15 billion, and adjusted EBITDA is forecasted to be $368-383 million as compared with the previous outlook of $365-380 million. release May 2, 2024
Full-year revenue is estimated at $2.08-$2.13 billion, and adjusted EBITDA is forecasted to be $368-$383 million. release Aug 7, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-22), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.